Drug intelligence / Profile preview

ebopiprant

Development stage: Phase 2
Lead developer: ObsEva
Modality: Small Molecules
Administration: Oral

Overview

Ebopiprant is an orally bioavailable, selective small molecule antagonist of the prostaglandin F2α (PGF2α) receptor. By inhibiting this receptor, ebopiprant aims to reduce uterine inflammation and contractions, thereby preventing cervical changes and membrane ruptures associated with preterm labor. It is being developed as a potential first-in-class treatment for preterm labor and has demonstrated proof of concept in delaying preterm birth in clinical trials. Ebopiprant was originally licensed from Merck KGaA by ObsEva and is now under global development by Organon[1][5][7].

Other names: 2005486-31-52005486-32-6

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on ebopiprant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ebopiprant.

Explore the full profile